NCT07201831Completed
A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
ACT on MASH: A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases. The study aims to collect valid responses through online questionnaires from the participants. This study is a survey-based study without collection of laboratory data. It will take the participant 25 minutes to complete the survey. The study is not related to any specific treatment options or pharmaceutical product.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1330 (actual)
- First submitted
- 18 Sept 2025
- Start date
- 2 Oct 2025
- Primary completion date
- 17 Jan 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07201831
What you commit to
- Study type: Observational
- Participants enrolled: 1330
- From 2 Oct 2025 to the primary completion date, 17 Jan 2026
- 5 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous participation in this study. Participation is defined as having given informed consent in this study
Other
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Who the study is looking for
- HCP inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan
- Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only)
- Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care
- Diagnosed patient inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months
- Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease
- At risk patient inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- Must have one or more risk factors associated with MASH \[obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease\], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Mississauga | Canada | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Mainz | Germany | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Puteaux | France | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
| Novo Nordisk Investigational Site Coordinator of this site? Confirm its status | Plainsboro | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.